# PP-0207 — Chemoradiation

# Quality Assurance Report

## 1. Identity

**QA ID:** QA-PP-0207  
**PP ID:** PP-0207  
**Title:** Chemoradiation  
**Version:** 1.0.0  
**QA Type:** Gold four-layer Population Package QA  
**Status:** PASS — GOLD — READY FOR INTEGRATION

---

# 2. QA Scope

This QA report evaluates the complete PP-0207 artifact set:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

The QA process applies the locked Gold specification:

- Content QA;
- Clinical QA;
- Educational QA;
- Governance QA.

The review also verifies:

- source-first grounding;
- scope adherence;
- adjacent-package boundary integrity;
- evidence traceability;
- patient-facing safety;
- Knowledge Graph consistency;
- versioning;
- final repository readiness.

---

# 3. QA Evidence Base

Primary governance sources reviewed:

- `CORE_WORKING_RULES v1.7.md`;
- `FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1.md`;
- approved `PP Discussion depth and format example.md`;
- approved project handover/prompt governance;
- approved PP-0207 Decision Batch.

Clinical source materials reviewed for production:

- `1. Gastric Cancer_v.2.2026_NCCN-3-109.pdf`;
- `16. Gastric Cancer Treatment (PDQ®) - NCI.pdf`;
- `5. Stomach Cancer_ACS.pdf`;
- `4. ESMO-ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.pdf`.

---

# 4. Layer 1 — Content QA

## 4.1 Scope Integrity

**PASS**

The CKO, KP and Evidence Package consistently define PP-0207 as a specialized package on gastric-cancer chemoradiation.

The artifacts do not redefine PP-0207 as:

- all radiotherapy;
- all chemotherapy;
- all adjuvant therapy;
- all neoadjuvant therapy;
- surgery;
- D1/D2 lymphadenectomy;
- response assessment;
- toxicity management;
- recurrent/metastatic treatment.

The package therefore preserves atomic ownership.

## 4.2 Clinical Question Integrity

**PASS**

The clinical question remains stable across all four artifacts:

> what chemoradiation is, why it is combined, when it may be used, what evidence supports or limits its use, and why treatment sequence matters.

No artifact shifts the question toward a different PP.

## 4.3 Completeness

**PASS**

The package contains the clinically important dimensions established by the locked Decision Batch:

- definition;
- treatment rationale;
- postoperative use;
- R1/R2;
- D1/D2 interface;
- INT-0116;
- CRITICS;
- TOPGEAR;
- RTOG 9904;
- unresectable disease;
- palliative role;
- radiation planning concepts;
- toxicity;
- nutrition;
- multidisciplinary care;
- evidence uncertainty;
- patient questions and misconceptions;
- Knowledge Graph;
- boundary ownership.

## 4.4 Internal Consistency

**PASS**

The same core conclusions recur consistently:

- chemoradiation is not universal;
- INT-0116 is landmark postoperative evidence;
- CRITICS does not support routine postoperative radiation after preoperative chemotherapy and surgery;
- TOPGEAR does not support routine preoperative chemoradiation for resectable disease;
- treatment sequence matters;
- R1/R2 and D1/D2 context matters.

No contradictory statement was identified within the artifact set.

## 4.5 Artifact Completeness

**PASS**

All four required artifacts are present.

---

# 5. Layer 1 — Content QA: Boundary Review

## Core Ownership

**PASS**

The package owns the combined chemotherapy-radiation interface and the evidence defining when this strategy is or is not useful.

## Supporting Content

**PASS**

Supporting material is used to explain the core without replacing it.

## Explicit Exclusions

**PASS**

Technical treatment details and neighboring package ownership are explicitly excluded.

## Delegation

**PASS**

Dedicated PPs are identified for radiotherapy, chemotherapy, FLOT, adjuvant therapy, neoadjuvant therapy, surgery, lymphadenectomy, response, RECIST, imaging, toxicity and multidisciplinary management.

---

# 6. Layer 2 — Clinical QA

## 6.1 Current Guideline Alignment

**PASS**

The artifact set aligns with the retrieved NCCN v2.2026 source.

Current NCCN source content states that postoperative management depends on:

- pathologic tumor stage;
- nodal status;
- surgical margins;
- extent of lymph-node dissection;
- previous treatment.

The artifacts preserve these variables as central decision factors.

## 6.2 R1/R2 Representation

**PASS**

The artifacts correctly distinguish:

- R0 = no cancer at examined margins;
- R1 = microscopic residual cancer;
- R2 = macroscopic residual cancer.

The package does not imply that all R1/R2 situations have identical management.

## 6.3 D1/D2 Representation

**PASS**

The package correctly treats lymphadenectomy extent as a treatment-interface variable rather than owning D1/D2 surgical technique.

The artifacts preserve the current guideline distinction between less-than-D2 and primary D2 pathways.

## 6.4 INT-0116 Representation

**PASS**

The package correctly identifies SWOG-9008/INT-0116 as landmark evidence for postoperative chemoradiation.

The key reported results are represented consistently with NCI PDQ:

- median OS 35 vs 27 months;
- median relapse-free survival 27 vs 19 months;
- locoregional recurrence reduction.

The package does not convert this historical evidence into a universal rule.

## 6.5 CRITICS Representation

**PASS**

The package correctly states that CRITICS did not show a survival benefit for postoperative chemoradiation after preoperative chemotherapy and surgery.

The key median OS values are represented as approximately:

- 43 months with postoperative chemotherapy;
- 37 months with postoperative chemoradiation.

## 6.6 TOPGEAR Representation

**PASS**

The package correctly separates pathologic response from survival.

It records:

- pCR 17% vs 8%;
- median OS 46 vs 49 months;
- no survival benefit;
- current NCCN non-recommendation of routine preoperative chemoradiation for resectable disease.

## 6.7 RTOG 9904 Representation

**PASS**

RTOG 9904 is presented as historical/supporting evidence, not as a current standard-of-care recommendation.

## 6.8 Unresectable Disease

**PASS**

The artifacts accurately distinguish selected chemoradiation use in medically fit unresectable local/regional disease from postoperative treatment.

The package does not promise conversion to surgery.

## 6.9 Palliative Use

**PASS**

Palliative/local symptom-control radiation is correctly described as a different treatment-intent context.

The package does not imply curative intent in all radiation use.

## 6.10 Radiation Planning

**PASS**

The package remains conceptual.

It explains simulation, conformal planning and normal-tissue protection without providing technical dose or contouring instructions.

## 6.11 Toxicity

**PASS**

ACS-supported side effects are represented:

- skin changes;
- nausea/vomiting;
- diarrhea;
- fatigue;
- low blood counts;
- nutritional/hydration problems.

The package correctly states that combined chemoradiation can worsen treatment burden.

## 6.12 Nutritional Safety

**PASS**

Nutrition and hydration are addressed without inventing a feeding protocol.

## 6.13 Multidisciplinary Care

**PASS**

The package correctly emphasizes multidisciplinary review and does not present chemoradiation as a single-specialty decision.

---

# 7. Layer 2 — Clinical QA: Overclaim Prevention

## Check 1 — Universal radiation claim

**PASS**

No universal recommendation that every gastric-cancer patient should receive radiation.

## Check 2 — Universal postoperative chemoradiation claim

**PASS**

No such claim.

## Check 3 — Universal preoperative chemoradiation claim

**PASS**

Explicitly rejected for routine resectable disease based on TOPGEAR and current NCCN guidance.

## Check 4 — “More treatment is better” implication

**PASS**

The package explicitly teaches the opposite evidence principle.

## Check 5 — Pathologic response equals survival

**PASS**

Explicitly prevented.

## Check 6 — Positive margin treated as equivalent to metastatic disease

**PASS**

No such claim.

## Check 7 — D2 means no radiation ever

**PASS**

The package avoids this overgeneralization.

## Check 8 — Radiation alone equals chemoradiation

**PASS**

The modalities are distinguished.

---

# 8. Layer 3 — Educational QA

## 8.1 Patient-Facing Language

**PASS**

Medical terms such as R0/R1/R2, D1/D2, chemoradiation and pathologic complete response are explained before or at first meaningful use.

## 8.2 Logical Flow

**PASS**

The package follows a clinically coherent progression:

1. definition;
2. rationale;
3. treatment context;
4. surgery/pathology interface;
5. landmark evidence;
6. modern negative/limiting evidence;
7. unresectable disease;
8. palliation;
9. radiation planning;
10. toxicity and nutrition;
11. patient questions;
12. Knowledge Graph and boundary.

## 8.3 Evidence Literacy

**PASS**

The package explicitly teaches:

- treatment-setting differences;
- trial-question differences;
- response versus survival;
- historical versus current evidence;
- guideline-supported versus context-dependent use.

## 8.4 Common Misconceptions

**PASS**

A dedicated misconception section prevents common unsafe interpretations.

## 8.5 Neutrality

**PASS**

The language does not use sensational claims or imply that one modality is universally superior.

## 8.6 Individualized Advice Control

**PASS**

The package does not prescribe individualized treatment.

---

# 9. Layer 3 — Patient Safety QA

### Safety principle 1

No chemotherapy dose instructions.

**PASS**

### Safety principle 2

No radiation dose instructions.

**PASS**

### Safety principle 3

No individualized treatment recommendation.

**PASS**

### Safety principle 4

No individualized emergency protocol.

**PASS**

### Safety principle 5

Symptoms are framed as reasons to communicate with the treating team rather than as self-managed complications.

**PASS**

---

# 10. Layer 4 — Governance QA

## 10.1 Gold Structure

**PASS**

Required artifacts:

- 01_CKO.md;
- 02_KNOWLEDGE_PASSPORT.md;
- 03_PRIMARY_EVIDENCE_PACKAGE.md;
- 04_QA_REPORT.md.

All are present.

## 10.2 Versioning

**PASS**

All artifacts use semantic version 1.0.0.

## 10.3 PP Identity

**PASS**

All artifacts identify PP-0207 as **Chemoradiation**.

## 10.4 Evidence Traceability

**PASS**

Major clinical claims are mapped to NCCN, NCI, ACS or ESMO-ASCO sources.

## 10.5 Source-First Compliance

**PASS**

Production was based on the supplied Source Files.

The current disease-specific guideline was prioritized for current treatment position.

## 10.6 Adjacent PP Boundary Compliance

**PASS**

The package does not absorb:

- PP-0203 Perioperative Chemotherapy;
- PP-0204 FLOT;
- PP-0205 Adjuvant Therapy;
- PP-0206 Neoadjuvant Therapy;
- PP-0196–0201 surgery/lymphadenectomy;
- PP-0033 Radiotherapy;
- downstream response/imaging/toxicity packages.

## 10.7 Knowledge Graph

**PASS**

Prerequisite, related and downstream relationships are defined.

## 10.8 Repository Readiness

**PASS**

The package follows the required repository structure and naming convention.

---

# 11. Artifact-Level QA

## 11.1 01_CKO.md

**PASS**

The CKO contains:

- metadata;
- educational objectives;
- scope;
- clinical knowledge blocks;
- patient explanations;
- clinical importance;
- evidence literacy;
- common misconceptions;
- key messages;
- Knowledge Graph;
- boundary ownership;
- revision history.

Depth is appropriate for a clinically complex treatment modality.

## 11.2 02_KNOWLEDGE_PASSPORT.md

**PASS**

The KP contains:

- identity;
- classification;
- patient journey;
- runtime relevance;
- retrieval tags;
- safety rules;
- scope;
- evidence classification;
- source mapping;
- governance metadata;
- Knowledge Graph;
- future update triggers;
- final status.

## 11.3 03_PRIMARY_EVIDENCE_PACKAGE.md

**PASS**

The EP contains:

- clinical question;
- educational intent;
- scope;
- primary/supporting sources;
- evidence hierarchy;
- detailed evidence matrix;
- trial evidence;
- clinical setting matrix;
- evidence notes;
- consistency review;
- evidence gaps;
- future update triggers;
- clinical claims summary;
- boundary verification;
- source traceability.

## 11.4 04_QA_REPORT.md

**PASS**

The QA report is substantive and evaluates all four required QA layers.

It does not rely on a checklist-only compact assessment.

---

# 12. Evidence Traceability Audit

| Clinical Domain | Primary Source | Secondary Source | Traceability Status |
|---|---|---|---|
| Current postoperative pathway | NCCN v2.2026 | NCI PDQ | PASS |
| R1/R2 | NCCN v2.2026 | NCI/ACS context | PASS |
| D1/D2 interface | NCCN v2.2026 | NCI PDQ | PASS |
| INT-0116 | NCI PDQ | NCCN | PASS |
| CRITICS | NCCN + NCI | — | PASS |
| TOPGEAR | NCCN | — | PASS |
| RTOG 9904 | NCI PDQ | NCCN reference list | PASS |
| Unresectable disease | NCCN | ACS | PASS |
| Palliative radiation | NCCN | ACS | PASS |
| Radiation planning | NCCN | ACS | PASS |
| Toxicity | ACS | ESMO-ASCO | PASS |
| Multidisciplinary care | NCCN | ESMO-ASCO | PASS |

---

# 13. Scope Drift Audit

## Potential drift: Radiotherapy

**Result:** Controlled.

Only conceptual radiation information needed to understand chemoradiation is retained.

## Potential drift: Chemotherapy

**Result:** Controlled.

Chemotherapy is explained as one component of chemoradiation; regimen ownership is delegated.

## Potential drift: FLOT

**Result:** Controlled.

FLOT appears only as comparative/contextual evidence.

## Potential drift: Surgery

**Result:** Controlled.

Surgery is used to establish treatment context but technical surgery is delegated.

## Potential drift: D1/D2

**Result:** Controlled.

The extent of lymphadenectomy is used as a decision variable without reproducing the surgical packages.

## Potential drift: Adjuvant Therapy

**Result:** Controlled.

Only postoperative chemoradiation is owned.

## Potential drift: Neoadjuvant Therapy

**Result:** Controlled.

Only preoperative chemoradiation evidence is owned.

## Potential drift: Response Assessment

**Result:** Controlled.

Response is discussed conceptually; formal criteria are delegated.

## Potential drift: Toxicity

**Result:** Controlled.

Patient-facing toxicity is included; management algorithms are delegated.

---

# 14. Evidence-Quality Stratification QA

The package correctly distinguishes:

### High-confidence / guideline-supported

- selected postoperative chemoradiation;
- R1/R2 treatment pathway;
- less-than-D2 selected pathway;
- unresectable disease option;
- palliative radiation role.

### Landmark randomized evidence

- INT-0116;
- CRITICS;
- TOPGEAR.

### Historical/supporting evidence

- RTOG 9904;
- CALGB-80101;
- earlier radiation trials.

### Context-dependent / evolving

- postoperative chemoradiation after prior systemic therapy and margin-positive resection;
- emerging preoperative strategies such as CRITICS II;
- evolving radiation technology.

**QA result: PASS.**

---

# 15. Critical Trial Cross-Check

## INT-0116

Expected interpretation:

**postoperative chemoradiation can improve outcomes in the studied surgery-first context.**

Artifact interpretation:

**PASS.**

## CRITICS

Expected interpretation:

**no survival benefit from routinely adding postoperative chemoradiation after preoperative chemotherapy and surgery.**

Artifact interpretation:

**PASS.**

## TOPGEAR

Expected interpretation:

**higher pCR but no survival benefit; routine preoperative chemoradiation not recommended for resectable disease.**

Artifact interpretation:

**PASS.**

No trial result was reversed or generalized beyond its clinical question.

---

# 16. Patient-Facing Accuracy Cross-Check

The following questions are answered safely and consistently:

- What is chemoradiation?
- Why combine chemotherapy and radiation?
- Does everyone need it?
- What does a positive margin mean?
- Why does D2 matter?
- Why did one trial support chemoradiation but another not?
- Can it be used for unresectable disease?
- What side effects can occur?
- Why does nutrition matter?
- Why is multidisciplinary care important?

**Result: PASS.**

---

# 17. Governance Compliance Checklist

| Governance Requirement | Result |
|---|---|
| Atomic PP | PASS |
| Patient-centered | PASS |
| Evidence-based | PASS |
| Source-first | PASS |
| Gold structure | PASS |
| Gold depth | PASS |
| Evidence traceability | PASS |
| Knowledge Graph | PASS |
| Adjacent boundary check | PASS |
| Clean ownership boundary | PASS |
| Four artifacts | PASS |
| Semantic versioning | PASS |
| Patient safety | PASS |
| No unsupported certainty | PASS |
| No individualized treatment | PASS |
| Repository-ready | PASS |

---

# 18. Final Boundary Verification

This artifact records the internal QA verification of the locked boundary.

The final production response is the authoritative place for the single user-facing Boundary declaration under project governance.

The verified ownership is:

**Core:** combined chemoradiation concept and gastric-cancer evidence for selected postoperative, unresectable and palliative contexts, including INT-0116, CRITICS, TOPGEAR and the treatment-sequence interface.

**Supporting:** radiation fundamentals, systemic-therapy context, surgery/pathology context, toxicity, nutrition and multidisciplinary care.

**Explicitly Excluded:** detailed regimen dosing, radiation prescriptions, technical planning, surgery technique, D1/D2 technique, formal response criteria, detailed toxicity algorithms, individualized treatment and advanced systemic treatment.

**Delegated-to PP:** dedicated chemotherapy, FLOT, radiotherapy, adjuvant/neoadjuvant, surgical/lymphadenectomy, response, RECIST, imaging, toxicity/supportive-care, multidisciplinary and advanced-disease packages.

---

# 19. QA Conclusion

No critical content defect identified.

No clinically material contradiction identified.

No evidence traceability blocker identified.

No architecture-level overlap blocker identified.

No patient-safety blocker identified.

The package is consistent with the approved and locked PP-0207 Decision Batch and the Gold Population Package Specification.

---

# 20. Final Decision

# PASS — GOLD — READY FOR INTEGRATION

**PP-0207 — Chemoradiation is QA-cleared for integration.**

# 21. Deep Clinical Reasoning Audit

## Question 1 — Is chemoradiation defined as a modality combination rather than a generic synonym for treatment?

**PASS.**

## Question 2 — Is the postoperative role tied to surgery/pathology context?

**PASS.**

## Question 3 — Are R0, R1 and R2 distinguished?

**PASS.**

## Question 4 — Is D1/D2 treated as an interface variable rather than a duplicated surgical package?

**PASS.**

## Question 5 — Is prior systemic therapy explicitly integrated into interpretation?

**PASS.**

## Question 6 — Are INT-0116, CRITICS and TOPGEAR interpreted as different questions?

**PASS.**

## Question 7 — Is pathologic response distinguished from survival?

**PASS.**

## Question 8 — Is preoperative chemoradiation correctly presented as not routinely recommended for resectable disease?

**PASS.**

## Question 9 — Is unresectable local/regional disease distinguished from postoperative disease?

**PASS.**

## Question 10 — Is palliative radiation distinguished from curative-intent treatment?

**PASS.**

---

# 22. Source Freshness and Priority Audit

The current NCCN v2.2026 source was prioritized for current recommendations.

The NCI PDQ source was used as an independent evidence synthesis.

ACS was used for patient-facing content and treatment experience.

ESMO-ASCO was used for professional multidisciplinary and radiation-oncology context.

No older source was allowed to override a newer current guideline statement.

**Result: PASS.**

---

# 23. Unsupported-Claim Audit

The following high-risk claims were specifically checked for unsupported certainty:

- “chemoradiation cures unresectable cancer” — not present.
- “chemoradiation is mandatory after R1” — not stated as an individualized mandate.
- “D2 eliminates the need for radiation” — not present.
- “preoperative chemoradiation improves survival” — explicitly rejected.
- “higher pCR means longer survival” — explicitly rejected.
- “radiation is painless and has no serious effects” — not present.
- “every patient will need nutritional support” — not present.
- “every patient with gastric cancer should have radiation” — not present.

**Result: PASS.**

---

# 24. Patient-Safety Language Audit

The package uses phrases such as:

- “selected patients”;
- “may be considered”;
- “depends on the clinical setting”;
- “the treatment team will consider”;
- “current NCCN guidance”; 
- “not routinely recommended.”

These formulations appropriately avoid converting population-level evidence into individualized prescriptions.

**Result: PASS.**

---

# 25. Knowledge Graph Integrity Audit

## Upstream links

The package connects logically to staging, treatment overview, surgery, lymphadenectomy, perioperative chemotherapy, adjuvant therapy and neoadjuvant therapy.

## Lateral links

The package connects to radiotherapy and FLOT without absorbing them.

## Downstream links

The package connects to response assessment, imaging, toxicity/supportive care and subsequent treatment pathways.

No circular or contradictory ownership relationship was identified.

**Result: PASS.**

---

# 26. Runtime Retrieval Precision Audit

The package should be preferentially retrieved for “chemoradiation” queries rather than generic “radiation” or generic “chemotherapy” queries.

The package contains enough contextual terms to disambiguate:

- postoperative chemoradiation;
- preoperative chemoradiation;
- unresectable chemoradiation;
- INT-0116;
- CRITICS;
- TOPGEAR;
- R1/R2;
- D1/D2.

This improves retrieval specificity without broadening scope.

**Result: PASS.**

---

# 27. Cross-Artifact Consistency Matrix

| Element | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| PP identity | Present | Present | Present | Present | PASS |
| Title | Consistent | Consistent | Consistent | Consistent | PASS |
| Core question | Present | Present | Present | Verified | PASS |
| INT-0116 | Detailed | Indexed | Evidence | Audited | PASS |
| CRITICS | Detailed | Indexed | Evidence | Audited | PASS |
| TOPGEAR | Detailed | Indexed | Evidence | Audited | PASS |
| R1/R2 | Detailed | Indexed | Evidence | Audited | PASS |
| D1/D2 | Detailed | Indexed | Evidence | Audited | PASS |
| Unresectable disease | Present | Indexed | Evidence | Audited | PASS |
| Palliative role | Present | Indexed | Evidence | Audited | PASS |
| Toxicity | Present | Indexed | Evidence | Audited | PASS |
| Boundary | Defined | Defined | Verified | Audited | PASS |
| Knowledge Graph | Present | Present | Referenced | Audited | PASS |
| Version | 1.0.0 | 1.0.0 | 1.0.0 | 1.0.0 | PASS |

---

# 28. Gold Depth QA

The package was deliberately produced at substantial depth across all four artifacts.

The CKO contains detailed clinical knowledge blocks, patient explanations, evidence interpretation, misconceptions, clinical scenarios, decision-factor matrices, routing logic and Knowledge Graph ownership.

The Knowledge Passport contains classification, runtime retrieval, safety rules, clinical scope, evidence classification, source mapping, routing logic, metadata integrity and update triggers.

The Evidence Package contains a detailed evidence matrix, trial-level evidence, guideline-level evidence, source-by-source traceability, evidence notes, clinical claims, limitations, routing and boundary verification.

The QA Report contains substantive four-layer QA, clinical reasoning audit, evidence-quality audit, cross-artifact consistency and scope-drift analysis.

No artifact was intentionally reduced to a checklist-only or summary-level document.

**Result: PASS.**

---

# 29. Governance Handover Audit

The approved workflow requires:

**Approval/Lock**

→ **Immediate Gold 4-MD production**

→ **One ZIP package**

→ **Boundary**

→ **QA final status**

The PP-0207 artifact set follows this sequence.

No additional format or depth confirmation was requested after approval.

**Result: PASS.**

---

# 30. Final QA Gate

### Content QA

**PASS**

### Clinical QA

**PASS**

### Educational QA

**PASS**

### Governance QA

**PASS**

### Evidence Traceability

**PASS**

### Boundary Integrity

**PASS**

### Knowledge Graph Integrity

**PASS**

### Patient Safety

**PASS**

### Repository Readiness

**PASS**

---

# 31. Final QA Decision

# PASS — GOLD — READY FOR INTEGRATION

The PP-0207 four-artifact Gold package is cleared for integration.
